|
|
Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion in Subjects with Pulmonary and Pleural Malignancies
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outline Trial Contact Information Related Information Registry Information
Alternate Title
Decitabine and FR901228 in Treating Patients With Advanced Lung Cancer, Esophageal Cancer, Pleural Mesothelioma, or Lung Metastases
Basic Trial Information
Phase | Type | Status | Age | Protocol IDs |
---|
Phase I | Treatment | Active | 18 and over | NCI-02-C-0205 NCI-5270, 5270, NCT00041158 |
Special Category:
NIH Clinical Center trial Objectives - Determine the pharmacokinetics, toxicity, and maximum tolerated dose of decitabine and FR901228 (depsipeptide) in patients with unresectable pulmonary, esophageal, or pleural malignancies.
- Determine serologic response to NY-ESO-1 in these patients before and after receiving this regimen.
- Evaluate apoptosis in tumor biopsies of these patients before and after receiving this regimen.
Entry Criteria Disease Characteristics:
- Histologically or cytologically confirmed primary small cell lung cancer
(SCLC), non-small cell lung cancer (NSCLC), advanced esophageal cancer, or pleural mesothelioma
- Cancers of non-thoracic origin with metastases to the
lungs or pleura
eligible
- Unresectable disease
- Primary or metastatic disease must be accessible for biopsy by
endoscopic or
percutaneous fine-needle aspiration techniques
- No limited stage SCLC or operable NSCLC
- No active intracranial or leptomeningeal metastases
- Patients with prior intracranial metastases that have
been treated with prior
surgery or radiotherapy are eligible provided there
is no evidence of active
disease and no requirement for anticonvulsant therapy or steroids
after treatment
Prior/Concurrent Therapy:
Biologic therapy: - At least 30 days since prior anticancer biologic therapy
Chemotherapy: - At least 30 days since prior anticancer chemotherapy
- Prior decitabine or FR901228 (depsipeptide) allowed provided no dose-limiting
toxicity was experienced at the scheduled dose
Endocrine therapy: - See Disease Characteristics
Radiotherapy: - See Disease Characteristics
- At least 14 days since prior localized radiotherapy to
non-target lesions and recovered
- At least 30 days since prior anticancer radiotherapy
Surgery: - See Disease Characteristics
Other: - No more than 2 prior systemic cytotoxic treatment regimens
- At least a 5 half-life washout period since and no concurrent medication causing corrected QT interval (QTc) prolongation
- No concurrent medication causing corrected QTc prolongation
- No concurrent anticonvulsants
- No concurrent hydrochlorothiazide diuretics
- No concurrent digitalis
Patient Characteristics:
Age: Performance status: Life expectancy: Hematopoietic: - Absolute neutrophil count at least 1,500/mm3 (without cytokine
support)
- Platelet count greater than 100,000/mm3 (without
transfusion)
Hepatic: - Bilirubin less than 1.5 times upper limit of normal
- PT normal
Renal: - Creatinine no greater than 1.6 mg/dL
OR - Creatinine clearance greater than 70 mL/min
Cardiovascular: - LVEF less than 50% by MUGA scan or echocardiogram
- No New York Heart Association class III or IV heart
disease (i.e., decompensated heart failure)
- No myocardial infarction within the past year
- No uncontrolled arrhythmias
- No prior serious ventricular arrhythmias not controlled by
coronary artery bypass surgery
- No prosthetic heart valves requiring anticoagulation
- No deep venous thrombosis
- No left ventricular hypertrophy
- No history of sustained ventricular tachycardia, ventricular fibrillation, Torsades de Pointes, or cardiac arrest without currently having an automatic implantable cardioverter defibrillator in place
- No congenital long QT syndrome or QTc > 480 msec
- No Mobitz II second degree block without currently having a pacemaker in place
- No cardiac arrhythmias requiring antiarrhytmic medication except a beta blocker or calcium channel blocker
- No hypertrophic or restrictive cardiomyopathy from prior treatment of other causes
- No uncontrolled hypertension (i.e., blood pressure ≥160/95)
- No clinically significant active myocardial ischemia on the basis of nuclear imaging or angiography
- No history of coronary artery disease (e.g., angina Canadian Class II-IV or positive stress imaging study)
- No evidence of cardiac ischemia (e.g., ST depression greater than or equal to 2 mm) by EKG
- First degree or Mobitz second degree block, bradyarrhythmias, or sick sinus syndrome allowed provided patient undergo Holter monitoring and cardiac evaluation
Pulmonary: - FEV1 and DLCO greater than 30% predicted
- Partial pressure of carbon dioxide (pCO2) less than 50 mm Hg
on room air
- Partial pressure of oxygen (pO2) greater than 60 mm Hg on room
air
- No pulmonary embolism
Other: - Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No active infections
- HIV negative
Expected Enrollment 40A maximum of 40 patients will be accrued for this study within 10.8-13.5 months. Outline This is a dose-escalation study. Patients receive decitabine IV continuously on days 1-3 and FR901228 (depsipeptide) IV
over 4 hours on days 4 and 10. Courses repeat every 33-36 days in the absence
of disease progression or unacceptable toxicity. Sequential dose escalation of decitabine is followed by sequential dose
escalation of FR901228. Cohorts of 3-6 patients receive escalating doses of
decitabine and then FR901228 until the maximum tolerated dose (MTD) is
determined. The MTD is defined as the dose preceding that at which 2 of 6
patients experience dose-limiting toxicity. Once the MTD is determined, two additional cohorts (6 lung cancer and 6 mesothelioma patients) receive decitabine and FR901228 as above at the MTD. These patients also receive oral celecoxib twice daily on days 4-34 of each course.
Trial Contact Information
Trial Lead Organizations NCI - Center for Cancer Research | | | David Schrump, MD, Protocol chair | | | | Trial Sites
|
|
|
|
U.S.A. |
|
Maryland |
|
|
Bethesda |
|
| | | | | | | | NCI - Center for Cancer Research |
| | Tricia Kunst, RN | |
| Email:
tricia_kunst@nih.gov |
| | Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office |
| | Clinical Trials Office - Warren Grant Magnusen Clinical Center - NCI Clinical Trials Referral Office | |
|
Related Information Web site for additional information
Registry Information | | Official Title | | Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion in Subjects with Pulmonary and Pleural Malignancies | | Trial Start Date | | 2002-05-21 | | Trial Completion Date | | 2003-07-15 (estimated) | | Registered in ClinicalTrials.gov | | NCT00041158 | | Date Submitted to PDQ | | 2002-05-16 | | Information Last Verified | | 2008-11-30 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|